# A FULL LIST OF ABSTRACTS TO BE PRESENTED BY JANSSEN AT THE 2018 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING IN CHICAGO, IL ON JUNE 1-5

| ABSTRACT NO. | TITLE | DATE/TIME |
|---|---|---|
| **Erdafitinib** | | |
| Abstract #4503[1] | First Results from the Primary Analysis Population of the Phase 2 Study of Erdafitinib (ERDA; JNJ-42756493) in Patients (pts) with Metastatic or Unresectable Urothelial carcinoma (mUC) and FGFR alterations (FGFRalt) | Oral Presentation<br>Sunday, June 3<br>9:00 – 9:12 a.m. CDT |
| **Imbruvica®▼ (ibrutinib)*** | | |
| Abstract #8003[2] | Randomized Phase 3 Trial of Ibrutinib/Rituximab vs Placebo/Rituximab in Waldenstrom Macroglobulinemia | Oral Presentation<br>Friday, June 1<br>3:45 – 3:57 p.m. CDT |
| Abstract #7502[3] | Phase 2 CAPTIVATE Results of Ibrutinib (ibr) Plus Venetoclax (ven) in First-line Chronic Lymphocytic Leukemia (CLL) | Oral Presentation<br>Sunday, June 3<br>10:09 – 10:21 a.m. CDT |
| Abstract #7521[4] | Prognostic Role of Beta-2 Microglobulin (B2M) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Ibrutinib (ibr) | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #2578[5] | A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib plus Durvalumab in Patients with Relapsed/Refractory Solid Tumors | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| **Darzalex®▼ (daratumumab)** | | |
| Abstract #8002[6] | Daratumumab (DARA) in Combination with Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide (Len)-Refractory Patients (Pts) with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 | Oral Presentation<br>Friday, June 1<br>3:09 – 3:21 p.m. CDT |
| Abstract #8013[7] | Subcutaneous Daratumumab (DARA) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) | Poster Discussion<br>Monday, June 4<br>8:00 - 11:30 a.m. CDT |
| Abstract #8011[8] | Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients (Pts) with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA | Poster Discussion<br>Monday, June 4<br>8:00 - 11:30 a.m CDT |
| Abstract #8031[9] | Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (≥75 y) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation (ALCYONE) | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #TPS8059[10] | Pomalidomide and Dexamethasone (pom-dex) With or Without Daratumumab (DARA) in Patients (pts) With Relapsed or Refractory Multiple Myeloma (RRMM): a Multicenter, Randomized, Phase 3 Study (APOLLO) | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #TPS8058[11] | Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #8042[12] | Improved Health-related Quality of Life for Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Stem Cell Transplantation: Results from the ALCYONE Trial | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #TPS8062[13] | Randomized, Open-Label, Phase 3 Study of Subcutaneous Daratumumab (DARA SC) Versus Active Monitoring in Patients (Pts) With High-risk Smoldering Multiple Myeloma (SMM): AQUILA | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |
| Abstract #TPS8057[14] | Randomized, Open-label, Phase 2/3 Study of Daratumumab (DARA) With or Without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM) | Poster Session<br>Monday, June 4<br>8:00 – 11:30 a.m. CDT |

*Abstracts were submitted by IMBRUVICA co-developer partner, Pharmacyclics, an AbbVie company.

PHEM/JAN/0518/0002a
Date of preparation: May 2018

| ABSTRACT NO. | TITLE | DATE/TIME |
|---|---|---|
| **Apalutamide** | | |
| Abstract #5033[15] | Relationship of Time to Metastasis (TTM) and Site of Metastases in Patients (Pts) with Non-Metastatic Castration-Resistant Prostate Cancer (nmCPRC): Results from the Phase 3 SPARTAN Trial | Poster Discussion<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| Abstract #5034[16] | Predicting Disease Progression in Patients (Pts) with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): An Analysis from the Phase 3 SPARTAN Trial | Poster Discussion<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| **Zytiga® (abiraterone acetate)** | | |
| Abstract #5028[17] | Subsequent Treatment After Abiraterone Acetate + Prednisone (AA + P) In Patients (Pts) With Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer (NDx-HR mCNPC): Detailed Analyses from the Phase 3 LATITUDE Trial | Poster Discussion<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| Abstract #5023[18] | Longer Term Preplanned Efficacy and Safety Analysis of Abiraterone Acetate + Prednisone (AA + P) in Patients (Pts) with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer (NDx-HR mCNPC) from the Phase 3 LATITUDE Trial | Poster Discussion<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| Abstract #5067[19] | Clinical Qualification of Plasma Androgen Receptor (pAR) Status and Outcome on Abiraterone Acetate (AA) Plus Prednisone or Dexamethasone (+P/D) in a Phase II Multi-Institutional Study in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Poster Session<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| Abstract #5038[20] | A Transcriptome Analysis of Castration-Resistant Prostate Cancer Metastases in a Prospective Cohort Study Reveals High Expression of AKT Pathway Genes Predictive of Long Term Response to Abiraterone Acetate/Prednisone | Poster Session<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |
| **Prostate Cancer** | | |
| Abstract #5032[21] | Association of Metastasis-Free Survival (MFS) and Overall Survival (OS) in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) | Poster Discussion<br>Saturday, June 2<br>1:15 – 4:45 p.m. CDT |

## REFERENCES


1. Siefker-Radtke AO, et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 4503.
2. Dimopoulos MA, et al. Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8003.
3. Wierda WG, et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 7502.
4. Wierda WG, et al. Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 7521.
5. Hong DS, et al. A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 2578.
6. Chari A, et al. Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): subgroup analysis of MMY1001. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8002.
7. Chari A, et al. Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8013.
8. Comenzo R, et al. Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: safety run-in results of ANDROMEDA. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8011.
9. Cavo M, et al. Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8031.
10. Sonneveld P, et al. Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): a multicenter, randomized, phase 3 study (APOLLO). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract TPS8059.
11. Usmani SZ, et al. Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract TPS8058.
12. Gries K, et al. Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: results from the ALCYONE trial. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 8042.
13. Rajkumar SV, et al. Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract TPS8062.
14. Van Droogenbroeck J, et al. Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract TPS8057.
15. Smith MR, et al. Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): results from the phase 3 SPARTAN trial. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5033.
16. Small EJ, et al. Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5034.
17. Chi KN, et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5028.
18. Fizazi K, et al. Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5023.
19. Jayaram A, et al. Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5067.
20. Kohli M, et al. A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone. To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5038.
21. Smith MR et al. Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC). To be presented at 2018 ASCO Annual Meeting, Chicago, IL, USA, 1-5 June 2018; abstract 5032.



PHEM/JAN/0518/0002a
Date of preparation: May 2018